In patients with stage 3 CKD , adverse events were reported over 52 weeks by 156 patients ( 83 % ) on placebo ( 15 severe [ 8 % ] and 23 serious [ 12 % ] ) and 156 ( 83 % ) on empagliflozin 25 mg ( 18 severe [ 10 % ] and 22 serious [ 12 % ] ) .